Bayer to unveil late-breaking data from Phase III OASIS 1 and 2 for elinzanetant in the treatment of vasomotor symptoms associated with menopause

BERLIN--(BUSINESS WIRE)--Bayer will present detailed results from the pivotal Phase III studies OASIS 1 and 2, evaluating the efficacy and safety of the investigational compound elinzanetant versus placebo, at the upcoming American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting. ACOG takes place from May 17 – 19, in San Francisco, CA, United States. Additional presentations will feature new findings from Bayer’s intrauterine systems (IUS) and menopaus